Will AbbVie's Oncology Drugs Aid Top Line in 2026?

Key Takeaways AbbVie expects 2026 oncology sales of $6.5 billion, down from 2025 due to lower Imbruvica pricing.Newer drugs like Epkinly, Elahere and Emrelis are driving growth, offsetting Imbruvica declines.AbbVie is advancing ADCs and pipeline candidates to strengthen its oncology portfolio.AbbVie (ABBV) has built a significant presence in the oncology space. While the majority of the revenues are generated from blood cancer drugs Imbruvica and Venclexta, the company has diversified its offerings with new ...